COVID-19 Specific Immune Markers Revealed by Single Cell Phenotypic Profiling

Sansico, Francesca; Miroballo, Mattia; Bianco, Salvatore Daniele; Tamiro, Francesco; Colucci, Mattia; Santis, Elisabetta De; Rossi, Giovanni; Rosati, Jessica; Mauro, Lazzaro Di; Miscio, Giuseppe; Mazza, Tommaso; Vescovi, Angelo L.; Mazzoccoli, Gianluigi; Giambra, Vincenzo

doi:10.3390/biomedicines9121794

Cited by 5 publications

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously shown [19], immunophenotypic changes in T cell compartment are associated to SARS-CoV-2 infection, highlighting the relevance of T-cells in the innate and virus specific immune response. The evidence of the lack of prompt T cell response in cirrhotic patients as compared to HW is the other original finding of our study.…”

Section: Discussionsupporting

confidence: 55%

Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: LC has been associated with hyporesponsiveness to several vaccines. Nonetheless, no data on complete serological and B- and T-cell immune response are currently available. Aims: To assess, in comparison with healthy controls of the same age and gender, both humoral and cellular immunoresponses of patients with LC after two or three doses of the mRNA Pfizer-BioNTech vaccine against SARS-CoV-2 and to investigate clinical features associated with non-response. Material and methods: 179 patients with LC of CTP class A in 93.3% and viral etiology in 70.1% of cases were longitudinally evaluated starting from the day before the first dose to 4 weeks after the booster dose. Their antibody responses were compared to those of healthcare workers without co-morbidities. In a subgroup of 40 patients, B- and T-cell responses were also compared to controls. Results: At d31, d90 and d180 after BNT162b2 vaccine, no detectable SARS-CoV-2 IgG response was observed in 5.9%, 3.9% and 7.2% of LC patients as compared to 0 controls (p < 0.03). A delay in B-cell and lack of prompt T-cell response compared to healthcare workers was also registered. A significant correlation between antibody titers and cellular response was observed. A MELD score > 8 was the only independent predictor of poor d31 response (p = 0.028). Conclusions: Our results suggest that cirrhotic patients have a slower and in <10% suboptimal immune response to SARS-CoV-2 vaccination. Rates of breakthrough infections were comparable between cirrhotics and controls. The booster dose was critical in inducing both humoral and cellular responses comparable to controls.

show abstract

Section: Discussionsupporting

confidence: 55%

Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…In critically ill COVID-19 patients, the host immune response is thought to play a key role in driving acute pneumonia with diffuse alveolar injury, inflammatory infiltration and microvascular thrombosis 61 . Expression of cell receptors (such as IFNGR1 and CXCR4) was reduced by a viral infection and is associated with suppression of associated signaling pathways and immune function 62 . A systematic evaluation in 2020 estimated that 28% of patients with severe COVID-19 had venous thromboembolism.…”

Section: Discussionmentioning

confidence: 99%

Identification of the effects of COVID-19 on patients with pulmonary fibrosis and lung cancer: a bioinformatics analysis and literature review

Yang

Niu

2022

Sci Rep

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) poses a serious threat to human health and life. The effective prevention and treatment of COVID-19 complications have become crucial to saving patients’ lives. During the phase of mass spread of the epidemic, a large number of patients with pulmonary fibrosis and lung cancers were inevitably infected with the SARS-CoV-2 virus. Lung cancers have the highest tumor morbidity and mortality rates worldwide, and pulmonary fibrosis itself is one of the complications of COVID-19. Idiopathic lung fibrosis (IPF) and various lung cancers (primary and metastatic) become risk factors for complications of COVID-19 and significantly increase mortality in patients. Therefore, we applied bioinformatics and systems biology approaches to identify molecular biomarkers and common pathways in COVID-19, IPF, colorectal cancer (CRC) lung metastasis, SCLC and NSCLC. We identified 79 DEGs between COVID-19, IPF, CRC lung metastasis, SCLC and NSCLC. Meanwhile, based on the transcriptome features of DSigDB and common DEGs, we identified 10 drug candidates. In this study, 79 DEGs are the common core genes of the 5 diseases. The 10 drugs were found to have positive effects in treating COVID-19 and lung cancer, potentially reducing the risk of pulmonary fibrosis.

show abstract

“…[ 52 ] Interestingly, another study with Caucasian participants showed that low levels of CXCR4 were associated with COVID‐19. [ 53 ] Due to contradictory results, more studies are required to determine the function of CXCR4 . This might also be variation among different ethnic groups.…”

Section: Chemokine Receptormentioning

confidence: 99%

Host Genetic Impact on Infectious Diseases among Different Ethnic Groups

Naidoo,

Arumugam,

Ramsuran

2023

Advanced Genetics

View full text Add to dashboard Cite

Infectious diseases such as malaria, tuberculosis (TB), human immunodeficiency virus (HIV), and the coronavirus disease of 2019 (COVID‐19) are problematic globally, with high prevalence particularly in Africa, attributing to most of the death rates. There have been immense efforts toward developing effective preventative and therapeutic strategies for these pathogens globally, however, some remain uncured. Disease susceptibility and progression for malaria, TB, HIV, and COVID‐19 vary among individuals and are attributed to precautionary measures, environment, host, and pathogen genetics. While studying individuals with similar attributes, it is suggested that host genetics contributes to most of an individual's susceptibility to disease. Several host genes are identified to associate with these pathogens. Interestingly, many of these genes and polymorphisms are common across diseases. This paper analyzes genes and genetic variations within host genes associated with HIV, TB, malaria, and COVID‐19 among different ethnic groups. The differences in host–pathogen interaction among these groups, particularly of Caucasian and African descent, and which gene polymorphisms are prevalent in an African population that possesses protection or risk to disease are reviewed. The information in this review could potentially help develop personalized treatment that could effectively combat the high disease burden in Africa.

show abstract

COVID-19 Specific Immune Markers Revealed by Single Cell Phenotypic Profiling

Cited by 5 publications

References 51 publications

Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response

Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response

Identification of the effects of COVID-19 on patients with pulmonary fibrosis and lung cancer: a bioinformatics analysis and literature review

Host Genetic Impact on Infectious Diseases among Different Ethnic Groups

Contact Info

Product

Resources

About